{"filing":{"accession_number":"0001437749-26-025509","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"crvo20260803_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/crvo20260803_8k.htm"},"events":[{"id":23957,"run_id":21669,"accession_number":"0001437749-26-025509","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"CervoMed announced that neflamapimod has been granted an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway (ILAP) for dementia with Lewy bodies, providing early and coordinated guidance from the MHRA, NICE, and other HTA bodies designed to accelerate time to market. This is a material regulatory milestone affecting the development pathway and competitive positioning of the company's lead drug candidate.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24323,"accession_number":"0001437749-26-025509","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced that neflamapimod has been granted an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway (ILAP) for dementia with Lewy bodies. This is a regulatory milestone that provides \"early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE), and other HTA bodies\" and is designed to \"accelerate time to market.\" While this is a positive regulatory development for the company's lead drug candidate, it does not fit neatly into the specific event categories (not an earnings release, executive change, M\u0026A activity, impairment, or other defined types). As a material regulatory/operational milestone affecting the development pathway of the company's lead program, operational_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:34:01.478947+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24324,"accession_number":"0001437749-26-025509","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"CervoMed announced that neflamapimod has been granted an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway (ILAP) for treatment of Dementia with Lewy Bodies. This is a regulatory milestone and strategic achievement that provides \"early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and health technology assessment (HTA) bodies\" and is designed to \"accelerate time to market.\" While this is a positive regulatory development for a clinical-stage biotech company's lead candidate, it does not fit neatly into the specific event categories (not an earnings release, executive change, M\u0026A activity, impairment, or other named types). It is clearly operational/strategic in nature—a material regulatory milestone that would affect investor assessment of the company's development pathway and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:34:01.478947+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24323,"accession_number":"0001437749-26-025509","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced that neflamapimod has been granted an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway (ILAP) for dementia with Lewy bodies. This is a regulatory milestone that provides \"early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE), and other HTA bodies\" and is designed to \"accelerate time to market.\" While this is a positive regulatory development for the company's lead drug candidate, it does not fit neatly into the specific event categories (not an earnings release, executive change, M\u0026A activity, impairment, or other defined types). As a material regulatory/operational milestone affecting the development pathway of the company's lead program, operational_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:34:01.478947+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-08-04"},{"id":24324,"accession_number":"0001437749-26-025509","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"CervoMed announced that neflamapimod has been granted an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway (ILAP) for treatment of Dementia with Lewy Bodies. This is a regulatory milestone and strategic achievement that provides \"early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and health technology assessment (HTA) bodies\" and is designed to \"accelerate time to market.\" While this is a positive regulatory development for a clinical-stage biotech company's lead candidate, it does not fit neatly into the specific event categories (not an earnings release, executive change, M\u0026A activity, impairment, or other named types). It is clearly operational/strategic in nature—a material regulatory milestone that would affect investor assessment of the company's development pathway and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:34:01.478947+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-08-04"}]}